Israel’s PainReform (see here previously) has developed new improved anti-inflammatory properties for its PRF-110 pain relief treatment. These have then been successfully tested in a Phase 3 multi-site US trial of 443 patients undergoing bunionectomy surgery. https://painreform.com/releases/painreform-announces-positive-safety-profile-for-prf-110-in-phase-3-bunionectomy-study/ https://painreform.com/releases/painreform-announces-development-and-successful-manufacturing-of-new-formulations-providing-anti-inflammatory-and-extended-analgesic-effects/

Israel’s PainReform has just completed a Phase 3 human trial of its PRF-110 post-operative pain relief. The oil-based, viscous, clear solution is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. https://painreform.com/releases/painreform-announces-positive-safety-data-in-first-part-of-phase-3-clinical-trialof-prf-110-in-patients-undergoing-bunionectomy-surgery/